Quantum Computing’s $6 Billion ETF Is Up 54% This Year, And It Is Still Earlier Than the AI Trade Was in 2022
📈 The Defiance Quantum ETF (QTUM) has gained 54.2% year-to-date and 98.72% over the last year with $6 billion in assets.
🔬 IBM's Heron processor is a 156-qubit chip currently used for molecular chemistry, paving the way for the Quantum Starling system.
💻 Google's Willow quantum processor executed a calculation in 5 minutes that would take supercomputers 10 septillion years.
📊 QTUM holds a 5-star Morningstar rating and tracks the BlueStar Machine Learning and Quantum Computing Index.
🏢 The ETF portfolio mixes pure-play quantum firms like IonQ with tech stalwarts like Intel and Micron for stability.
🧬 Applications are expanding into medicine, finance, cybersecurity, and climate modeling using qubit architecture.
💡 Investors are advised to allocate 1-3% of portfolios to the sector while adopting an incremental investment strategy.
- QTUM has delivered exceptional returns with a +54.20% gain year-to-date and nearly doubling in value over the past year.
- The ETF features a low 0.4% expense ratio, making it cost-effective for investors seeking exposure to quantum technology.
- Major tech giants like IBM and Alphabet are actively commercializing breakthroughs, reducing reliance on early-stage startups alone.
- IBM's Heron processor is already proving superior functionality over current supercomputers in specific scientific fields.
- Google's Willow chip demonstrated a massive speed advantage, solving problems in minutes that would take traditional computers millennia.
- The sector offers limitless application potential across engineering, medicine, finance, and cybersecurity industries.
- QTUM provides diversification by including established tech companies alongside pure-play quantum computing firms.
- Many pure-play quantum computing companies in the portfolio are currently pre-revenue or deeply in the red.
- The field remains highly volatile, with a significant risk that some companies may fail despite technological promise.
- Commercialization timelines for widespread industry adoption remain uncertain and dependent on future breakthroughs.